William Gorday1, Hossein Sadrzadeh2, Lawrence de Koning3, Christopher Naugler4. 1. Calgary Laboratory Services, Calgary, Alberta, Canada; Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada. Electronic address: Bill.Gorday@cls.ab.ca. 2. Calgary Laboratory Services, Calgary, Alberta, Canada; Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada. Electronic address: Hossein.Sadrzadeh@cls.ab.ca. 3. Calgary Laboratory Services, Calgary, Alberta, Canada; Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada. Electronic address: Lawrence.DeKoning@cls.ab.ca. 4. Calgary Laboratory Services, Calgary, Alberta, Canada; Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada; Department of Family Medicine, University of Calgary, Calgary, Alberta, Canada. Electronic address: Christopher.Naugler@cls.ab.ca.
Abstract
OBJECTIVES: There are conflicting recommendations regarding the use of prostate specific antigen (PSA) as a screening test. Integral to this debate is an understanding of who is currently being tested. The purpose of this study was to provide a detailed account of PSA testing practices in a major Canadian city (Calgary, Alberta) and to identify variables that may affect access to the PSA test. DESIGN AND METHODS: PSA test counts were retrieved from Calgary Laboratory Services' Laboratory Information System from January 1, 2011 to December 31, 2011. A total of 75,914 individual PSA tests were included in our analysis. The frequency of PSA testing was plotted onto a dissemination area map of Calgary using ArcGIS software. Associations with sociodemographic variables were tested using Poisson regression. RESULTS: The median PSA value was 0.93 μg/L and the median age at collection was 58 years. Forty-three percent of men aged 60-69 received a PSA test. Visible minority status 'Black' (P=0.0002) and Métis status (P=0.0075) were associated with lower PSA testing frequencies, while median household income (P=<0.0001) and university education (P=<0.0001) were associated with higher PSA testing frequencies. CONCLUSION: There are areas in Calgary which are significantly over or under tested relative to the mean. The amount of PSA testing in men <50 years of age is increasing, which is contrary to PSA testing guidelines.
OBJECTIVES: There are conflicting recommendations regarding the use of prostate specific antigen (PSA) as a screening test. Integral to this debate is an understanding of who is currently being tested. The purpose of this study was to provide a detailed account of PSA testing practices in a major Canadian city (Calgary, Alberta) and to identify variables that may affect access to the PSA test. DESIGN AND METHODS: PSA test counts were retrieved from Calgary Laboratory Services' Laboratory Information System from January 1, 2011 to December 31, 2011. A total of 75,914 individual PSA tests were included in our analysis. The frequency of PSA testing was plotted onto a dissemination area map of Calgary using ArcGIS software. Associations with sociodemographic variables were tested using Poisson regression. RESULTS: The median PSA value was 0.93 μg/L and the median age at collection was 58 years. Forty-three percent of men aged 60-69 received a PSA test. Visible minority status 'Black' (P=0.0002) and Métis status (P=0.0075) were associated with lower PSA testing frequencies, while median household income (P=<0.0001) and university education (P=<0.0001) were associated with higher PSA testing frequencies. CONCLUSION: There are areas in Calgary which are significantly over or under tested relative to the mean. The amount of PSA testing in men <50 years of age is increasing, which is contrary to PSA testing guidelines.
Authors: Zachary Klaassen; Christopher J D Wallis; Hanan Goldberg; Thenappan Chandrasekar; Neil E Fleshner; Antonio Finelli; Girish S Kulkarni; Allan S Detsky; Raj Satkunasivam Journal: Can Urol Assoc J Date: 2018-06-19 Impact factor: 1.862
Authors: Stephen J Freedland; Adriana C Vidal; Lauren E Howard; Martha K Terris; Matthew R Cooperberg; Christopher L Amling; Christopher J Kane; William J Aronson Journal: Cancer Date: 2017-06-27 Impact factor: 6.860
Authors: Paul Nderitu; Mieke Van Hemelrijck; Mark Ashworth; Rohini Mathur; Sally Hull; Alexandra Dudek; Simon Chowdhury Journal: BMJ Open Date: 2016-07-12 Impact factor: 2.692